Literature DB >> 99311

Studies on the effects of propanolol on plasma catecholamine levels in patients with essential hypertension.

K H Rahn, H W Gierlichs, G Planz, R Planz, M Schols, W Stephany.   

Abstract

The influence of the beta receptor blocking agent propranolol on plasma catecholamine concentrations was studied in eight patients with essential hypertension. The study was of single blind crossover design. Propranolol given in oral doses ranging from 60 to 240 mg daily for a period of 3 weeks decreased blood pressure and heart rate. The beta-adrenergic blocking agent caused plasma catecholamine levels to increase both at rest and during bicycle exercise. Chromatographical analysis showed that concentrations of noradrenaline as well as of adrenaline rose during treatment with propranolol. However, dopamine-beta-hydroxylase activity in plasma was not altered. Furthermore, the urinary excretion of noradrenaline, adrenaline and 4-hydroxy-3-methoxy mandelic acid did not change during beta receptor blockade. The results are compatible with the assumption that antihypertensive doses of propranolol by decreasing cardiac output cause an activation of the sympatho-adrenal system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 99311     DOI: 10.1111/j.1365-2362.1978.tb00827.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  15 in total

1.  Comparison of beta-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol).

Authors:  J Erikssen; E Thaulow; R Mundal; P Opstad; S Nitter-Hauge
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

2.  Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity.

Authors:  R Kirsten; B Heintz; D Böhmer; K Nelson; S Roth; D Welzel
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise.

Authors:  G Planz; R Planz
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

5.  Exercise-induced increments in plasma levels of propranolol and noradrenaline.

Authors:  G A Hurwitz; J G Webb; T Walle; S A Bai; H B Daniell; L Gourley; C Boyd Loadholt; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

6.  Elevated plasma noradrenaline in response to beta-adrenoceptor stimulation in man.

Authors:  H H Vincent; A J Man In't Veld; F Boomsma; G J Wenting; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

7.  The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertension.

Authors:  M J Vandenburg; J M Holly; F J Goodwin; V L Sharman; F P Marsh
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension.

Authors:  A J Man in 't Veld; G J Wenting; F Boomsma; R P Verhoeven; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

9.  Adrenergic mechanisms in control of plasma lipid concentrations.

Authors:  J L Day; J Metcalfe; C N Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-17

10.  Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol.

Authors:  R Vandongen; B Margetts; N Deklerk; L J Beilin; P Rogers
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.